Detalhe da pesquisa
1.
Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Br J Cancer
; 121(3): 281, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31123346
2.
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
Br J Cancer
; 120(6): 612-620, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30792533
3.
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Breast Cancer Res Treat
; 120(2): 409-18, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19418217
4.
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Mod Pathol
; 23(1): 27-37, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19898424
5.
Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
Clin Cancer Res
; 18(16): 4375-84, 2012 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22745105
6.
Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.
Mol Cancer Ther
; 11(8): 1770-80, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22665524
7.
The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3ß-dependent pathway.
Mol Cancer Ther
; 10(6): 949-59, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21471285
8.
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.
J Mol Diagn
; 13(5): 504-13, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21726664